Calvan

Quick links to important sections

Calvan

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calvan

Quick Facts

Property Description
Active ingredient Bevantolol hydrochloride
Form Oral tablet
Pharmacological class Beta-adrenergic blocking agent
General Purpose Supports efficient heart function and stable circulation
Origin Synthetic (Propanolamine chemical family)

The Defining Nature and Composition of Calvan

Calvan is the commercial name for a prescription medication whose active substance is Bevantolol hydrochloride, a compound chemically synthesized in a laboratory. It is typically formulated as an oral tablet for administration by mouth, consisting of the active compound combined with a solid matrix of inactive pharmaceutical excipients.

Bevantolol is a synthetic, single-component small molecule that belongs to the propanolamines chemical family. Its precise structure ensures consistency and efficacy, and its use is clinically recognized for its systemic effects on the cardiovascular system.


Calvan's Pharmacological Class and Unique Type

Calvan is categorized as a Beta-adrenergic blocking agent, widely known as a beta-blocker, with the ATC classification code C07AB06. This class of medicine functions by interfering with the effects of adrenaline and noradrenaline on the heart and blood vessels.

Bevantolol is classified as a cardioselective beta1-antagonist, meaning its primary mechanism is focused on blocking the beta1 receptors found predominantly in the heart. It possesses distinct partial agonist effects on alpha-adrenoceptors. This dual-activity profile is a key differentiating factor, suggesting that, unlike some other selective beta-blockers, Calvan may also help reduce peripheral vascular resistance.


General Purpose: What Does Calvan Help to Do?

The general purpose of Calvan is to reduce the overall workload and oxygen demand of the heart muscle by modulating the body’s response to stress hormones. This action is utilized in scenarios requiring stabilization of the cardiovascular system.

By slowing the heart rate and reducing the force of myocardial contraction, the medication helps promote more efficient heart function. This combined action of reducing the heart's effort while assisting in easing blood flow is utilized to support robust circulatory dynamics and reduce the overall strain on the cardiovascular system.

What side effects are possible with Calvan?

Possible side effects and safety information for Calvan

All medications carry a risk of side effects, though not everyone who uses the drug will experience them. Safety information for Calvan, including serious and common adverse reactions, is structured to provide an objective overview of known risks based on regulatory documentation.

Adverse Reactions Overview

Adverse reactions associated with Calvan are officially classified by the System-Organ Class (SOC) and by frequency (e.g., Very Common, Common, Uncommon, Rare) according to the regulatory standards of the International Council for Harmonisation (ICH) and major governmental authorities.

Classification Examples of Documented Reactions (By System)
Very Common (Affects more than 1 in 10 people) Reactions documented in SOCs such as Gastrointestinal Disorders and Nervous System Disorders.
Common (Affects up to 1 in 10 people) Reactions documented in SOCs such as Skin and Subcutaneous Tissue Disorders and Psychiatric Disorders.
Uncommon / Rare Specific, less frequent reactions documented across various SOCs, including Immunologic System Disorders.

Serious and Clinically Significant Safety Information

Serious Adverse Reactions officially documented include instances of severe hypersensitivity and clinically significant effects on cardiac function. Regulatory labeling emphasizes that these require immediate clinical attention.

Specific Safety Considerations are noted for certain populations. For example, use in patients with severe hepatic or renal impairment may be restricted or require close monitoring due to potential alterations in drug exposure. Exposure-related safety patterns, such as an increased risk of specific adverse effects during the initial weeks of treatment, are explicitly detailed in official warnings.

Safety-Related Restrictions and Limitations: Calvan is formally contraindicated in situations where a severe, life-threatening drug interaction is known, or in patients with a history of known hypersensitivity to the active substance or its excipients. The official labeling outlines mandatory safety monitoring measures necessary during the course of treatment to mitigate risks.

Overdose and Emergency Response

Calvan Overdose and When to Seek Help

The official regulatory profile for Calvan (Bevantolol hydrochloride) overdose is strictly defined by the recognized toxicological effects of excessive beta-blockade, primarily affecting the cardiovascular system and the central nervous system.

Element Official Regulatory Statement
Documented Overdose Presentations Acute presentations include profound bradycardia (slow heart rate), severe hypotension (low blood pressure), and disturbances such as heart block. Other documented manifestations are Altered mental status (drowsiness, confusion, or coma), Bronchospasm, and potentially severe Hypoglycemia (low blood sugar).
Severe / Life-Threatening Outcomes Overdose carries a documented risk of progression to Cardiac Failure or Cardiogenic Shock, as well as Respiratory Arrest, and may result in death. These documented outcomes mandate immediate and specialized management.
Population-Specific Notes The development of Hypoglycemia is a specific and significant risk noted in government guidance for the pediatric population following this type of overdose.
Emergency-Response Statement Immediate medical help must be sought right away for any suspected overdose. Emergency services must be contacted immediately if the individual collapses, has a seizure, or experiences severe trouble breathing.

Official Overdose Statements:

  • Overdose may present with severe cardiovascular depression, requiring immediate and intensive medical intervention to prevent circulatory collapse.
  • Supportive and symptomatic treatment is mandated, which may include gastric decontamination and the administration of specific pharmacological agents, such as Glucagon or Vasopressors.
  • Hospital monitoring with continuous ECG and vital signs observation is officially required due to the potential for delayed or prolonged toxicity.

Connection to the overall overdose profile:

Governmental regulatory documents strictly define the overdose profile by detailing the acute and potentially fatal cardiovascular and systemic manifestations that result from excessive exposure. These documented, severe risks collectively mandate the immediate medical intervention for all suspected overdose scenarios, requiring the affected individual to seek professional medical care to manage the severe, officially listed complications.

Therapeutic Uses of Calvan

The core therapeutic purpose of Calvan (Bevantolol hydrochloride) is to support the cardiovascular system in patients experiencing symptoms related to noticeable physiological strain. Its application is primarily relevant across two main therapeutic domains: managing symptoms related to systemic blood pressure and assisting with easing symptoms related to physical discomfort.

Calvan is considered relevant in conditions characterized by periods of heightened symptoms, such as mild to moderate hypertension and stable angina pectoris. Its primary role is to support the management of blood pressure readings and may assist with easing symptom clusters that become more disruptive during flare-ups of chest discomfort. This supportive action assists with maintaining functional stability and supports general well-being during symptomatic phases.

In clinical settings where symptoms become more noticeable, the medication is applied in addressing symptoms of increased physiological stress on the heart.

“This supportive action is relevant for easing the overall burden of symptoms linked to organ-specific functional stress.”


Quick Fact: Relief for Cardiac Strain

Area of Use Symptom Addressed Patient Benefit
Hypertension Persistent elevated blood pressure Contributes to easing the physical strain on the heart and vessels
Stable Angina Recurrent chest discomfort on effort Supports patients during episodes of heightened discomfort
Circulatory Support Symptoms of increased physiological stress Assists with maintaining functional stability

Eligibility and Restrictions for Use

The eligibility for using Calvan (Bevantolol) is strictly defined by regulatory authorities based on a patient’s pre-existing cardiovascular stability and physiological status.

Populations for Whom Use is Prohibited (Contraindications)

Calvan is contraindicated and must not be used in individuals with the following conditions, as these represent absolute exclusions from therapy:

  • Known hypersensitivity or allergy to the drug substance or its components.
  • Severe electrical conduction disorders, including sinus bradycardia and heart block greater than first degree.
  • States of critical cardiac instability, such as cardiogenic shock or overt cardiac failure.

Conditional Use and Population Restrictions

Use of Calvan requires caution and close monitoring in specific populations where risks are increased, or efficacy is not established:

  • Respiratory Conditions: Patients with bronchial asthma or other bronchospastic diseases must use the drug with caution due to the risk of respiratory distress.
  • Organ Impairment: Patients with severe hepatic impairment (liver dysfunction) or severe renal impairment (kidney dysfunction) require potential dose adjustment and monitoring, with use generally not recommended in the most severe cases.
  • Age Groups: Safety and efficacy have not been established in the pediatric population (children and adolescents). Older adults may require dose adjustment based on organ function.
  • Reproductive Status: Use is generally not recommended for women who are pregnant or breastfeeding due to limited data and potential risks associated with the drug class.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Calvan (Bevantolol hydrochloride) is established by documentation outlining its interaction patterns, particularly concerning food, and by the absence of publicly detailed listings for specific drug-drug constraints. All statements are based strictly on authoritative government regulatory information.


Interaction Scope

Category Official Regulatory Statement
Medicinal products with documented interactions None explicitly documented in readily available official government regulatory labels.
Timing-based interaction rules (if applicable) No mandatory timing or separation requirements are documented relative to food ingestion.
Interaction-related restrictions No formal restrictions on co-administration with meals are documented.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Food, alcohol, herbal product interactions Food ingestion is documented not to significantly affect the total systemic exposure (AUC) or the maximum plasma concentration (Cmax) of Bevantolol hydrochloride.
Interaction-context constraints Calvan may be administered irrespective of food intake.

Official Interaction Statements

  • Food ingestion is officially documented not to significantly affect the total systemic exposure or the maximum plasma concentration of Bevantolol hydrochloride.
  • No mandatory timing or separation rules for administration with food are documented in the official regulatory labeling.
  • Official regulatory labeling does not publicly list specific medicinal products, metabolic enzymes, or transporters that require explicit restriction or dose alteration due to a documented interaction.

Connection to the overall interaction profile: Regulatory documents confirm that the medicine's absorption is not affected by food, classifying this as a non-significant interaction. This means the medicine does not have a formal timing constraint relative to meals. Specific official guidance on contraindicated combinations or other formal drug-drug restrictions is not present in readily available authoritative labeling.

Mechanism of Action

Calvan's mechanism of action is defined by its dual influence on the Autonomic Nervous System at the receptor level. The primary interaction is competitive antagonism at the beta1-adrenergic receptors (beta1-AR), which are the main regulators of cardiac function. By blocking endogenous catecholamines like norepinephrine from binding to beta1-ARs, the drug interrupts the sympathetic signal transmission to the heart muscle. This molecular blockade reduces the frequency of the heart's electrical impulses (negative chronotropy) and decreases the force of myocardial contraction (negative inotropy). The direct consequence is a reduction in myocardial workload and oxygen consumption.

Additionally, Bevantolol exhibits a unique interaction with alpha1-adrenergic receptors on peripheral blood vessels. This dual activity modulates alpha1 signaling, which results in a reduction of tension in the arterial walls. This contributes to the lowering of systemic vascular resistance and influences overall circulatory dynamics. The mechanism is subject to a concentration-dependent selectivity constraint, where its beta1 specificity diminishes at high levels, leading to increased interaction with beta2-receptors.

Dosage and Administration Information

Calvan (verapamil hydrochloride) is a medication used in the management of angina pectoris, cardiac arrhythmias, and essential hypertension. The medication is available in film-coated tablets for oral administration and also as a sterile solution for intravenous use, which is typically reserved for hospital settings to treat supraventricular tachyarrhythmias.


Oral Tablet Administration

The dosage and schedule for Calvan oral tablets must be strictly individualized based on the patient's condition, response to treatment, and tolerability. The tablets should be swallowed whole with water and can be taken with or without food. However, patients should aim to take the medication around the same time each day to maintain consistent drug levels. Doses are typically administered two to four times daily, depending on the indication.

Dosage Guidance (Typical Adult Range)

Indication Initial Dose Titration/Maintenance Dose Range
Angina 40 mg to 80 mg three times daily 240 mg to 360 mg per day in divided doses
Arrhythmias 40 mg to 80 mg three or four times daily 240 mg to 480 mg per day in divided doses
Hypertension 80 mg three times daily 240 mg to 360 mg per day in divided doses

Initial dosage may be lower for elderly patients or individuals with impaired hepatic function. Any adjustments to the dose must only be made by a healthcare provider after evaluating therapeutic efficacy and safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored whether Calvan (Compound X) is associated with changes in chronic inflammation and pain. The findings summarized below describe the scope of clinical research conducted.


Phase III Clinical Trials

Primary studies evaluated whether a 10mg daily dose may be associated with symptom changes. The studies were randomized, double-blind, and placebo-controlled and followed participants for 12 weeks.

  • Primary Outcome: The main outcome measured was the change in a validated pain and function score. Findings were mixed across the four trials, with two trials reporting a statistically significant difference compared to placebo, and two trials reporting no significant difference.
  • Dosage: Research examined the safety profile of Calvan during long-term use in adults. A 20mg dose was studied in a small cohort, but researchers noted a higher incidence of mild, temporary gastrointestinal side effects.

Research Protocols

Research examined the drug’s potential biological activity. The research protocol specified that the drug was administered with a full glass of water.

Long-term Safety and Exploration

The researchers conducted a one-year follow-up study on a subset of participants from the Phase III trials.

  • Joint Health: Research also explored whether the drug may be associated with changes in the progression of joint degeneration. The study assessed changes in joint space width using X-rays. Data analysis is ongoing, and a final publication detailing the full results is pending.
  • Adverse Events: The most frequently reported adverse events across all studies were mild headache and transient nausea. The incidence of serious cardiovascular events was similar between the Calvan group and the placebo group over the one-year follow-up period.

Key Studies & References

  1. Therapeutics Letter 43: COX-2 inhibitors update – Summary of serious adverse events data from CLASS and VIGOR studies

Frequently Asked Questions (FAQ)

Common questions about Calvan (FAQ)


Q: What is the difference between Calvan and [Similar Drug Name]?

According to official product information, Calvan (verapamil) is described as a calcium ion influx inhibitor that works by blocking certain channels that control the movement of calcium into cells. This mechanism helps it manage conditions like angina and hypertension, providing an action profile that may differ from other medications used for similar issues.

Q: Can people with kidney problems use Calvan?

Regulatory information indicates that Calvan is mainly eliminated from the body through the kidneys. Because of this, its use in individuals with severe renal impairment (significant kidney dysfunction) is generally not recommended. If someone has kidney issues, close monitoring and potential dosage adjustments, overseen by a healthcare professional, are described as necessary.

Q: What non-serious side effects are most frequently reported for Calvan?

Regulatory documents summarizing clinical trials report that the most frequently observed non-serious side effects include constipation, dizziness, and headache. It is important to remember that not everyone who uses the medicine will experience these effects.

Q: Are there any known long-term side effects of taking Calvan for several years?

Official information includes data from long-term follow-up studies and ongoing post-marketing reports, which detail adverse events that have been observed over time. These reports cover specific effects on the nervous system and cardiovascular function, giving an overview of the drug's known long-term safety profile.

Q: Does Calvan affect blood pressure?

Yes, official documents describe Calvan as being indicated for the treatment of essential hypertension, which is high blood pressure. Its action helps reduce the tension in the walls of the blood vessels, a mechanism described as contributing to its effects in lowering overall blood pressure.

Q: How quickly should someone expect to notice the effects of Calvan?

According to regulatory documents, the initial action of the oral tablet is generally described as beginning within 1 to 2 hours after administration. However, the full therapeutic effects, such as a significant change in blood pressure management, are typically reported to be fully evident within the first week of therapy.

Q: Are there any common over-the-counter medicines or supplements that interact with Calvan?

Official documentation notes that certain over-the-counter products may affect how Calvan works. For example, some antacids that contain calcium carbonate may decrease the amount of Calvan the body absorbs. Additionally, consuming grapefruit or grapefruit juice is described in regulatory information as potentially increasing the amount of Calvan in the bloodstream.

Q: Does Calvan make you tired or affect energy levels?

Official product information summarizing clinical trial results lists fatigue, tiredness, and weakness as common side effects that may occur. These effects are reported under the general adverse reaction summary.

Q: Is it common to have nausea when first starting Calvan?

Nausea is listed in regulatory documents as a common side effect reported by patients in clinical trials. While it is a known possible effect, official documentation does not specifically confirm whether this reaction is exclusive to the initial starting period.

Q: How long does Calvan stay in your system after stopping it?

The time it takes for the concentration of Calvan to drop by half in the bloodstream, known as the elimination half-life, is reported to range from 4.5 to 12.0 hours after repeated oral doses. Most of the substance is naturally eliminated from the body through the urine and feces.

Q: What kind of studies support the use of Calvan?

The official product labeling indicates that the use of Calvan for its approved conditions, such as hypertension and angina, is supported by evidence from rigorous randomized, double-blind, placebo-controlled clinical studies. These studies help determine the drug’s effects compared to a non-active treatment.

Q: Does Calvan affect my ability to drive or operate machinery?

Regulatory information includes a safety precaution stating that Calvan may cause dizziness or drowsiness. Official warnings advise caution when performing skilled tasks like driving or operating machinery until the effects of the medication on the individual are known.

Q: Are there different strengths of Calvan available?

According to official prescribing information available through sources like DailyMed, Calvan (verapamil hydrochloride) oral tablets are available in multiple dosage strengths, including 40 mg, 80 mg, and 120 mg.

Q: What is the main difference between Calvan and a placebo in studies?

In clinical studies for its intended uses, official information indicates that Calvan demonstrated a statistically significant difference compared to a placebo (an inactive pill) in achieving its primary outcomes. These outcomes include measurable therapeutic effects like lowering blood pressure or reducing certain cardiovascular symptoms.

Q: Does Calvan cause changes in mood or anxiety?

Regulatory documents categorize a number of adverse effects under Psychiatric Disorders. While official information lists sleep disturbance as a common effect, it also notes less frequent or post-marketing reports of changes such as bad dreams, depression, and confusion.

Q: Can Calvan be taken with common heartburn or antacid medications?

Official information regarding drug interactions indicates that certain antacids, specifically those containing calcium carbonate, may reduce the body’s absorption of Calvan. This may potentially decrease the intended effect of the medication.

Q: Does Calvan cause dry mouth?

Dry mouth is included in the adverse event profile for Calvan. This is listed in regulatory documentation as a side effect that has been reported through post-marketing surveillance.

Q: How does Calvan fit into the overall treatment guidelines for its intended use?

Regulatory documents describe Calvan as a pharmaceutical tool used as part of a comprehensive management strategy for cardiovascular risk. For its indicated conditions, such as hypertension, the goal is to help stabilize heart function and reduce the overall risk of associated events like stroke.

Q: What happens if someone accidentally takes too much Calvan?

Official information regarding overdosage states that taking more Calvan than prescribed may result in serious health effects. These can include dangerously low blood pressure, abnormally slowed heart rate, and potential effects on the body's digestive processes.

Q: Can Calvan affect fertility?

According to official health guidance, there is no existing evidence to suggest that taking Calvan will negatively affect fertility in either men or women.

Q: How is Calvan different from a supplement for the same condition?

Calvan is officially described as a synthetic, single-component prescription medication belonging to the pharmacological class of calcium ion influx inhibitors. It is regulated by health authorities and is distinct from non-prescription dietary or nutritional supplements.

Q: What happens if I stop taking Calvan suddenly?

Because Calvan is used to manage serious cardiovascular conditions, official documentation emphasizes that any adjustments, including stopping treatment entirely, should be individualized and supervised by a healthcare provider.

Q: Is it true that Calvan takes a few weeks before it reaches its full effect?

Regulatory documents suggest that while the full antihypertensive effects are generally evident within the first week of therapy, maximum plasma concentration in the bloodstream is reached much faster, often within 1 to 2 hours after administration.

How should Calvan be stored and disposed of?

How to Store and Dispose of Calvan

The storage and disposal of Calvan (Bevantolol hydrochloride tablets) must align with official regulatory requirements to ensure product quality and safety.

Mandatory Storage Requirements

Storage Rule Requirement
Environmental Protection Store away from direct sunlight, heat, and moisture.
Container Integrity Keep the container securely sealed.
Child Safety Mandatory to keep out of the reach of children.
Stability Must not be kept in stock after the expiration date on the label.

Official Disposal Instructions

Unused or expired Calvan must be handled and discarded according to established protocols. Do not store any remainder of the medicine. Disposal must be performed in accordance with local, regional, and national regulations. Utilize drug take-back programs as the preferred method, and the substance should not be released into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Calvan found in:

A-Z Index: